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Background: Malignant melanoma is the most deadly form of skin cancer. Female sex is known to have a
protective effect on incidence, tumour characteristics, and mortality from melanoma. However, the potentially
modifying effect of sex on the prognostic significance of clinicopathological and investigative factors is generally
not taken into consideration in biomarker studies. In this study, we compared the sex-specific distribution and
prognostic value of established tumour characteristics and Ki67 expression in 255 cases of incident primary
melanoma in a prospective, population-based cohort study.
Methods: The study included 255 incident cases of melanoma, 132 females and 123 males, in the Malmö Diet and
Cancer Study. Tumours from 226 (88.6%) cases had been assembled in tissue microarrays. Clinicopathological
factors and immunohistochemical Ki67 expression were assessed and correlated with disease-free survival (DFS)
and overall survival (OS) using Kaplan-Meier analysis, log rank test and univariable and multivariable Cox regression
analyses, stratified for gender. Effect of gender on melanoma-specific survival (MSS) after first recurrence was
also analysed.
Results: Women were significantly younger at diagnosis than men (p = 0.012). The most common tumour sites
were the legs in women (37.5%) and the dorsal trunk in men (37.8%). Kaplan-Meier analysis revealed that tumour
location had no prognostic impact in women, but in men, location to the frontal trunk was significantly associated
with a reduced DFS compared with all other locations combined and location to the dorsal trunk was significantly
associated with a prolonged OS. High Ki67 expression was significantly associated with a reduced DFS and OS in
men but not in women, also when adjusted for other factors. In men, but not in women, ulceration was an
independent prognostic factor for both DFS and OS. MSS after first local, regional or distant recurrence was
significantly shorter for men than for women.
Conclusions: The results from this study demonstrate that the prognostic value of tumour location, Ki67 expression
and ulceration in melanoma differs according to gender. These findings need to be validated in future studies,
as they may help improve prognostication in patients with melanoma. Moreover, our findings demonstrate that
sex-stratified analyses add valuable information to biomarker studies.
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Malignant melanoma is an aggressive form of cancer with
an increasing incidence and mortality worldwide [1]. Once
a patient has moved into the stage of generalized disease,
survival is very poor [2,3], but the clinical course of melan-
oma is highly variable even in patients with thin melano-
mas and localized disease [4-6]. Despite increasing
insights into melanoma biology and advances in various
“omics” technologies [7-9], no prognostic biomarkers have
yet been incorporated into clinical protocols. One reason
for the difficulties in bridging this translational gap might
be that, while a protective effect of female gender on inci-
dence, tumour characteristics, and mortality from melan-
oma is evident [10,11], the prognostic value of putative
biomarkers is generally not evaluated differently in women
and men. The negative association of male gender with
survival from melanoma cannot solely be attributed to the
larger proportion of tumours with unfavourable clinico-
pathological characteristics, since gender remained prog-
nostic in several studies, also when adjusted for these
factors [2,10,12,13]. Moreover, women have been demon-
strated to have a prolonged survival compared to men
even after development of distant metastasis [14]. Taken
together, it is evident that hormonal and other sex-related
factors affect the clinical course of the disease and, there-
fore, sex-stratified analyses might add important informa-
tion to studies aiming at identifying novel prognostic and
treatment predictive biomarkers in melanoma. Biomarker
studies in other cancer forms affecting both sexes, e.g.
colorectal cancer, have indeed revealed a modifying effect
of sex on the prognostic value of certain markers [15,16].
In the present study, we examined the distribution and
prognostic value of clinicopathological characteristics of
melanoma, including Ki67 expression as an investigative
marker, in men and women, respectively. To this end,
we analysed 255 cases of incident malignant melanoma
in the prospective, population-based cohort Malmö Diet
and Cancer Study [17,18].
Methods
Patients
Until end of follow-up 31 December 2008, 264 incident
cases of malignant melanoma had been registered in the
prospective, population-based cohort study Malmö Diet
and Cancer Study (MDCS)[17]. Cases were identified
from the Swedish Cancer Registry up until 31 Dec 2007,
and from The Southern Swedish Regional Tumour
Registry for the period of 1 Jan-31 Dec 2008. Nine
(3.4%) cases for whom clinical and pathology records
were missing were excluded from the study, leaving 255
cases available for analysis. All tumours with available
slides and/or paraffin blocks were histopathologically re-
evaluated on haematoxylin and eosin stained slides
whereby information on lymphocytic infiltration (none,mild, moderate or brisk), ulceration (absent or present),
mitotic count and vascular invasion was obtained. Data
on location, Clark level and Breslow depth of invasion
was obtained from the clinical- and/or pathology
records. Information on recurrence (local, regional or
distant) was obtained in 2010 from patient records and
pathology reports. Information on vital status and cause
of death was obtained from the Swedish Cause of Death
Registry up until 31 Dec 2009. Follow-up started at date
of diagnosis and ended at death, emigration or 31 Dec
2009, whichever came first. Median follow-up time was
6.84 years (range 0.64-17.05) for the full cohort (n = 255)
and 7.29 years (range 1.10-17.05) for patients alive
(n = 202). Patient and tumour characteristics of the co-
hort have been described in detail previously [18]. Eth-
ical permission was obtained from the Ethics Committee
at Lund University for the MDCS (Ref. 51/90), and the
present study (Ref. 530/2008).
Tissue microarray construction and
immunohistochemistry
Paraffin-embedded tumour specimens were collected
from the archives of the pathology departments in the re-
gion of Skåne in southern Sweden. Tumours with an insuf-
ficient amount of material were excluded whereby 226/
255 (88.6%) cases were suitable for TMA construction.
Areas representative of cancer were then marked on
haematoxylin & eosin stained slides and TMAs con-
structed as previously described. In brief, three 0,6 mm
cores were taken from each tumour and mounted in a new
recipient block using semi-automated arraying device
(TMArrayer, Pathology Devices, Westminster, MD, USA).
The distribution of clinicopathological characteristics
was similar in tumours included in the TMA cohort
(total n = 226) and tumours not suitable for TMA con-
struction (total n = 29), except for histological subtype,
with no tumours being denoted as nodular in the lat-
ter category (0/23 vs 53/225, p = 0.005) but an equal
distribution of the other subtypes (data not shown).
For immunohistochemical analysis, 4 um TMA-
sections were automatically pre-treated using the PT-link
system (DAKO, Glostrup, Denmark) and then stained
in an Autostainer Plus (DAKO) using a monoclonal
anti- Ki67 antibody (MIB-1, DAKO, diluted 1:200). Ki67
expression was annotated as the fraction of positive stain-
ing cells and denoted as 0 (0-1%), 1(2-25%) and 2(>25%).
To check for heterogeneity, Ki67 expression was also ana-
lysed on full-face sections from 26 cases representing
tumours with varying thickness.
Statistical analysis
Chi-square, Spearman´s Rho and Mann Whitney U
tests were used for comparison of the distribution of
clinicopathological characteristics in the full cohort and
Table 1 Distribution of clinicopathological parameters in
women and men
n (% for columns) Female Male p-value






Dorsal trunk 20 (15.5) 45 (37.8)
Frontal trunk 15 (11.6) 19 (16.0)
Arms 29 (22.5) 18 (15.1)
Legs 51 (39.5) 13 (10.9)
Head and neck 14 (10.9) 24 (20.2)
Unknown 3 4
Histological type 0.372
SSM 80 (62.5) 80 (66.7)
NMM 27 (21.1) 26 (21.7)
LMM 16 (12.5) 13 (10.8)
Other 5 (3.9) 1 (0.8)
Unknown 4 3






< = 1 mm 86 (67.2) 72 (60.0)
1.1-2 mm 19 (14.8) 17 (14.2)
2.1-4 mm 17 (13.3) 23 (19.2)
>4 mm 6 (4.7) 8 (6.7)
Unknown 4 3
Clark level 0.999
II 46 (36.2) 47 (39.2)
III 57 (44.9) 46 (38.3)
IV 21 (16.5) 23 (19.2)
V 3 (2.4) 4 (3.3)
Unknown 5 3
Clinical stage 0.135
1A-B 98 (89.9) 81 (82.7)
2A-B 9 (8.3) 15 (15.3)
3-4 2 (1.8) 2 (2.0)
Unknown 23 25
Ulceration 0.962
No 111(86.0) 103 (85.8)
Yes 18 (14.09) 17 (14.2)
Unknown 3 3
Table 1 Distribution of clinicopathological parameters in
women and men (Continued)
Vascular invasion 0.076
No 123 (96.9) 109 (91.6)
Yes 4 (3.1) 10 (8.4)
Unknown 5 4
Mitotic count 0.769
0/mm2 69 (52.7) 62 (50.8)
>= 1/mm2 62 (47.3) 60 (49.2)
Unknown 3 1
Lymphocytic infiltrate 0.815
None-mild 38 (29.7) 34 (28.3)
Moderate-brisk 90 (70.3) 86 (71.7)
Unknown 4 3
Ki 67 expression 0.133
0-1% 4 (3.9) 11 (10.7)
2-25% 73 (70.9) 71 (68.9)





No 111 (84.1) 98 (79.7)
Yes 21 (15.9) 25 (20.3)
Vital status
Alive 114 (86.4) 88 (71.5)
Dead 18 (13.6) 35 (28.5) 0.004**
Dead from melanoma 9 (6.8) 19 (15.4) 0.028*
The p-values refer to comparisons of male and female tumours.
Mann–Whitney test for comparison of medians and Chi square test for
X × 2 tables. The categories marked as not done and unknown were not
included in the statistical analysis.
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was determined from the date of diagnosis of the pri-
mary melanoma to the date of diagnosis of the first
local, regional or distant recurrence or death from ma-
lignant melanoma. Overall survival (OS) was assessed
by calculating the risk of death from all causes, overall
mortality. Follow-up started at date of diagnosis and
ended at death, emigration or 31 Dec 2009, whichever
came first. Melanoma- specific survival (MSS) time was
calculated for patients who developed recurrent disease.
Follow-up started at date of diagnosis and ended at re-
current disease, death, loss to follow-up (emigration) or
last date of follow-up with regard to recurrent disease.
No recurrences were recorded following the last date of
follow-up regarding death, i.e. 31 Dec 2009. Follow-up
started at date of diagnosis and ended at death, emigra-
tion or 31 Dec 2009, whichever came first. Kaplan-
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differences in DFS, OS and MSS. Cox regression pro-
portional hazards models were used to estimate the im-
pact of the investigated parameters on survival in both
uni- and multivariable analysis. Co-variates were entered
into the multivariate analysis using backward selection.
The prognostic interaction between the clinicopathologi-
cal factors and gender was explored by a Cox model
including the interaction variable. All calculations were
performed using IBM SPSS Statistics Version 20 (SPSS
Inc, Chicago, IL). All statistical tests were two-sided and
a p value< 0.05 was considered statistically significant.
Results
Distribution of clinicopathological characteristics
according to gender
The distribution of clinicopathological characteristics
according to gender are shown in Table 1. Women were
significantly younger at diagnosis than men (p = 0.012).
There was also a sex-related difference in tumour loca-
tion, with the legs being the most common location in
women (39.5% vs 10.9% in men) and the dorsal trunkFigure 1 Kaplan-Meier estimates of the impact of tumour location an
men. Kaplan-Meier analysis of disease free survival according to tumour loc
0.228, 0.789 and 0.031, respectively), and overall survival according to tum
p-values 0.134, 0.556 and 0.075, respectively).being the most common location in men (37.8% vs
15.5% in women). Following antibody optimisation and
staining, Ki67 expression could be evaluated in 206/226
(91.1%) cases. There was an excellent concordance be-
tween Ki67 expression on full-face sections and corre-
sponding TMA cores. There was no significant difference
in Ki67 expression between the sexes. All other estab-
lished clinicopathological factors were evenly distributed
among both sexes (Table 1).
Prognostic value of clinicopathological characteristics in
women and men
Kaplan-Meier analysis revealed no significant difference
in the prognostic value of tumour location in the full co-
hort or in women (Figure 1A-B), while in men, anatomic
location was significantly associated with DFS (Figure 1C).
Similar trends were seen for OS, but none reached signifi-
cance (Figure 1 D-F). Univariable Cox regression analysis
confirmed the significant association of location to the
frontal trunk with a reduced DFS compared to all other
locations (HR= 3.06; 95% CI 1.36-6.89) in men, and loca-
tion to the dorsal trunk with a significantly prolongedd disease free and overall survival in the full cohort, women and
ation in (A) the full cohort, (B) women and (C) men (logrank p-values
our location in (D) the full cohort, (E) women and (F) men (logrank
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locations in men. These associations did however not re-
main significant in multivariable analysis, adjusted for the
other factors (data not shown). Univariable analyses did
not reveal any significant associations with DFS or OS
for the other locations (data not shown).
Nearly all established prognostic factors had a signifi-
cant impact on DFS in univariable analysis (Table 2), ex-
cept age (all categories), sex, tumour location (full cohort
and women), lymphocytic infiltration (women) and Ki67Table 2 Univariable and multivariable analyses of factors asso
women and men
Univariable





Continuous 1.01 (0.97-1.05) 1.00 (0.95-1.05) 1.01
Sex
Women 1.00 - -
Men 1.51 (0.85-2.70) - -
Histological subtype
LMM+ SSM 1.00 1.00 1.00
NMM 5.63 (3.15-10.08) 6.36 (2.67-15.12) 5.39
Breslow thickness
<=1 mm 1.00 1.00 1.00
> 1 mm 8.44 (4.27-16.68) 12.17 (4.07-36.34) 6.12
Clark level
II-III 1.00 1.00 1.00
IV-V 3.75 (2.11-6.69) 6.28 (2.65-14.89) 2.37
Ulceration
No 1.00 1.00 1.00
Yes 5.82 (3.13-10.80) 5.90 (2.41-14.42) 7.21
Clinical stage
1 1.00 1.00 1.00
2-4 15.02 (16.39-35.30) 25.41 (5.81-111.08) 11.76
Vascular invasion
No 1.00 1.00 1.00
Yes 9.25 (3.56-17.79) 20.48 (5.47-76.65) 6.87
Mitotic count
0/mm2 1.00 1.00 1.00
>= 1/mm2 7.95 (3.56-17.80) 27.24 (3.65-203.10) 4.83
Lymphocytic infiltrate
None-mild 1.00 1.00 1.00
Moderate-brisk 0.43 (0.24-0.78) 0.45 (1.19-1.08) 0.43
Ki67 expression
0-25% 1.00 1.00 1.00
>25% 2.46 (1.33-4.56) 1.67 (0.67-4.15) 4.06
LMM= lentigo maligna melanoma, SSM= superficial spreading melanoma, NMM=nexpression (women). After adjustment by all other vari-
ables, two factors retained an independent prognostic
value in the full cohort; clinical stage and vascular inva-
sion. In women, only vascular invasion remained an inde-
pendent predictor of a reduced DFS. In men, three factors
retained an independent prognostic value; ulceration, vas-
cular invasion, and Ki 67 expression (Table 2).
The relative risk of death (OS) according to the different
factors was also calculated, whereby age and male sex were










(0.95-1.07) 0.98 (0.94-1.02) 1.00 (0.94-1.06) 1.00 (0.92-1.09)
1.00 - -
1.06 (0.52-2.15) - -
1.00 1.00 1.00
(2.41-12.09) 1.21 (0.55-2.63) 1.47 (0.48-4.54) 1.49 (0.46-4.82)
1.00 1.00 1.00
(2.14-14.73 0.61 (0.10-3.70) 0.17 (0.01-2.95) 1.45 (0.15-14.22)
1.00 1.00 1.00
(1.07-5.22) 0.52 (0.26-1.03) 1.04 (0.32-3.43) 0.36 (0.12-1.07)
1.00 1.00 1.00
(2.97-17.48) 1.56 (0.65-3.76) 0.70 (0.23-2.12) 5.46 (1.70-17.53)
1.00 1.00 1.00
(3.86-35.87) 5.56 (3.02-24.28) 6.88 (1.64-28.89) 6.39 (1.56-26.25)
1.00 1.00 1.00
(2.96-15.97) 3.44 (1.63-7.25) 4.79 (1.21-19.01) 11.15 (3.42-36.38)
1.00 1.00 1.00
(1.92-12.13) 3.28 (1.11-9.73) 6.87 (0.77-61.05) 2.21 (0.53-9.13)
1.00 1.00 1.00
(0.19-0.94) 0.73 (0.37-1.44) 0.87 (0.31-2.43) 0.69 (0.25-1.90)
1.00 1.00 1.00
(1.74-9.48) 1.74 (0.85-3.54) 0.96 (0.24-3.78) 6.14 (1.76-21.39)
odular malignant melanoma.
















Continuous 1.09 (1.04-1.13) 1.08 (1.02-1.15) 1.08 (1.02–1.14) 1.07 (1.02-1.13) 1.09 (1.02-1.16) 1.10 (1.02-1.18)
Sex
Women 1.00 - - 1.00 - -
Men 2.60 (1.47-4.61) - - 1.89 (0.95-3.79) - -
Histological subtype
LMM+ SSM 1.00 1.00 1.00 1.00 1.00 1.00
NMM 3.86 (2.21-6.74) 3.93 (1.54-10.03) 4.17 (2.06-8.44) 2.73 (1.38-5.40) 3.35 (1.25-8.95) 2.88 (1.21-6.84)
Breslow thickness
<=1 mm 1.00 1.00 1.00 1.00 1.00 1.00
> 1 mm 4.17 (2.38-7.32) 4.53 (1.74-11.79) 3.66 (1.83-7.34) 0.73 (0.16-3.42) 0.56 (0.04-7.58) 0.58 (0.08-4.28)
Clark level
II-III 1.00 1.00 1.00 1.00 1.00 1.00
IV-V 2.27 (1.28-4.05) 1.87 (0.66-5.25) 2.22 (1.11-4.44) 0.84 (0.36-1.92) 0.53 (0.15-1.88) 1.10 (0.35-3.41)
Ulceration
No 1.00 1.00 1.00 1.00 1.00 1.00
Yes 6.29 (4.46-11.45) 5.83 (2.14-15.85) 7.33 (3.44-15.62) 2.63 (1.19-5.83) 1.01 (0.18-5.76) 3.34 (1.30-8.60)
Clinical stage
1 1.00 1.00 1.00 1.00 1.00 1.00
2-4 6.48 (3.05-13.73) 5.48 (1.43-21.04) 6.34 (2.49-16.14) 1.71 (0.57-5.08) 2.54 (0.59-10.89) 0.59 (0.11-3.29)
Vascular invasion
No 1.00 1.00 1.00 1.00 1.00 1.00
Yes 4.89 (2.38-4.08) 13.43 (2.84-63.50) 2.82 (1.23-6.50) 4.54 (1.90-10.84) 19.95 (3.63-109.75) 4.89 (1.66-14.41)
Mitotic count
0/mm2 1.00 1.00 1.00 1.00 1.00 1.00
>= 1/mm2 2.96 (1.66-5.28) 3.54 (1.26-9.96) 2.86 (1.41-5.82) 1.49 (0.65-3.40) 1.63 (0.34-7.81) 1.34 (0.44-4.07)
Lymphocytic infiltrate
None-mild 1.00 1.00 1.00 1.00 1.00 1.00
Moderate-brisk 0.46 (0.26-0.79) 0.53 (0.17-1.09) 0.45 (0.22-0.90) 0.66 (0.35-1.25) 1.03 (0.30-3.49) 0.60 (0.27-1.35)
Ki67 expression
0-25% 1.00 1.00 1.00 1.00 1.00 1.00
>25% 1.97 (1.06-3.64) 1.79 (0.66-4.87) 2.38 (1.09-5.22) 1.55 (0.73-3.30) 1.46 (0.34-6.14) 2.65 (1.08-6.52)
LMM= lentigo maligna melanoma, SSM= superficial spreading melanoma, NMM=nodular malignant melanoma.
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tors, the associations with OS were similar to DFS in uni-
variable analysis, with lymphocytic infiltration and Ki67
expression not being prognostic in women. After adjust-
ment by all other variables (Table 3), three factors retained
an independent prognostic value in the full cohort; nodular
histology, ulceration, and vascular invasion. In females,
nodular histology and vascular invasion remained inde-
pendent predictors of a reduced OS. In males, nodularhistology, ulceration, vascular invasion and Ki 67 expression
remained independent prognostic factors.
We also explored a possible interaction term between
sex and each prognostic factor for DFS and OS, but
found no significant effect.
The prognostic value of the RNA-binding motif 3
(RBM3) protein, previously demonstrated to be an inde-
pendent marker of good prognosis in this cohort [18] did
not differ according to gender (data not shown).
Fridberg et al. Biology of Sex Differences 2012, 3:16 Page 7 of 10
http://www.bsd-journal.com/content/3/1/16Impact of gender on survival after first recurrence
In light of previous findings of a more favourable out-
come in women after development of distant metastasis
[14], we also examined the impact of gender on MSS
and 2-year OS after first local, regional or distant recur-
rence (n = 46). Kaplan Meier analysis revealed a signifi-
cantly higher mortality from melanoma in men compared
to women (p= 0.039) (Figure 2A) as well as a significantly
higher mortality after 2 years (p= 0.038) (Figure 2B). The
significant association of male gender and shorter survival
from melanoma was also confirmed in univariable Cox re-
gression analysis (HR=2.29; 95% CI= 1.02-5.13, p = 0.044
for MSS and HR=2.64; 95% CI= 1.02-6.82, p = 0.046 for
2-year OS). For total OS, a similar, however non-
significant, trend, was seen (data not shown).Figure 2 Kaplan-Meier estimates of the impact of sex on
melanoma specific and overall survival after first recurrence.
Kaplan-Meier analysis of (A) melanoma-specific and (B) 2-year overall
survival according to gender after first local, regional or distant
recurrence.Associations of Ki67 expression with other
clinicopathological factors in the full cohort and
according to gender
In light of the differential prognostic impact of Ki67 ex-
pression in females and males, we examined whether the
association of Ki67 with other tumour and patient char-
acteristics might differ between the sexes. As demon-
strated in Table 4, the association of Ki67 and most
other factors were similar in both sexes, with the excep-
tion of Clark level and ulceration, for which no associa-
tions with Ki67 were seen in men, in contrast to a highly
significant association in women.
Discussion
In this study, we have demonstrated several sex-related
differences in the distribution and prognostic value of pa-
tient and tumour characteristics in malignant melanoma.
The significant difference in tumour location between the
sexes, with a predilection for tumours located to the ex-
tremities in women and the trunk in men, is in line with
the expected [11,13,14]. Interestingly, though, tumour lo-
cation was not prognostic in women, in contrast to men,
where melanomas located to the frontal trunk had a sig-
nificantly reduced DFS. Several studies have reported a
worse prognosis for melanomas located to the trunk [19-
22], and Balzi et al found a significantly improved prog-
nostic advantage for females over males with lesions
located on the trunk [14], which is in line with our find-
ings. It is however noteworthy that, in our study, where lo-
cation to the dorsal and frontal trunk were denoted as
separate categories, DFS was significantly poorer for men
having melanomas located to the frontal trunk compared
to the dorsal trunk. A similar trend was seen in the full co-
hort, but not in women. One explanation for trunk mela-
nomas having a worse prognosis might be that they often
drain to multiple lymph node basins [23], but the reason
for the here observed discrepant outcome between mela-
nomas located to the frontal and dorsal trunk in males,
evident for both DFS and OS, remains unclear and should
be considered in future studies related to the prognostic
significance of tumour site.
The MDCS is a population-based cohort study, and,
therefore, a potential selection bias compared to the gen-
eral population must be considered [24]. Since partici-
pants were>= 45 years at baseline, mean age at diagnosis
was higher than in the average population. Hence, in light
of the fact that high age is often associated with more
advanced melanoma [10], the comparatively low propor-
tion of cases with advanced melanoma is somewhat unex-
pected, and might indicate an increased awareness and
tendency to seek medical attention earlier among study
participants. In our study, women were significantly
younger at diagnosis than men. Although the life-time risk
of melanoma is higher in males than in females, a reversed
Table 4 Associations of Ki67 expression with clinicopathological factors in the full cohort, women and men
All Women Men
Ki67 expression Low High P Low High P Low High P
n(%) 159 (77.2) 47 (22.8) 77 (58.3) 26 (19.7) 82 (79.6) 21 (20.4)
Age
Continuous 68 (46–81) 70 (47–83) 0.233 66 (46–81) 69 (47–83) 0.366 70 (53–80) 72 (55–80) 0.317
Location
Dorsal trunk 43 (28.1) 10 (21.3) 0.120 13 (17.3) 3 (11.5) 0.135 30 (38.5) 7 (33.3) 0.520
Frontal trunk 19 (12.4) 4 (8.5) 7 (9.3) 1 (3.8) 12 (15.4) 3 (14.3)
Arms 27 (17.6) 9 (19.1) 17 (22.7) 6 (23.1) 10 (12.8) 3 (14.3)
Legs 44 (28.8) 27.7) 33 (44.0) 11 (42.3) 1 (14.1) 2 (9.5)
Head and neck 20 (13.1) 11 (23.4) 5 (6.7) 5 (19.2) 15 (19.2) 6 (28.6)
Unknown 6 0 2 0 4 0
Histological subtype
SSM, LMM, Other 130 (82.3) 24 (51.1) <0.001 63 (81.8) 14 (53.8) 0.004 67 (82.7) 10 (47.6) 0.001
NMM 28 (17.7) 23 (48.9) 14 (18.2) 12 (46.2) 14 (17.3) 11 (52.4)
Unknown 1 0 0 0
Breslow thickness
<=1 mm 107 (68.2) 15 (31.9) <0.001 54 (71.1) 9 (34.6) 0.001 53 (65.4) 6 (28.6) 0.002
>1 mm 50 (31.8) 32 (68.1) 22 (28.9) 17 (65.4) 28 (34.6) 15 (71.4)
Unknown 2 0 0 0 1 0
Clark level
II-III 128 (81.5) 28 (60.9) 0.004 64 (84.2) 14 (56.0) 0.004 64 (79.0) 14 (66.7) 0.237
IV-V 29 (18.5) 18 (39.1) 12 (15.8) 11 (44.0) 17 (21.0) 7 (33.3)
Unknown 2 1 2 1 1 0
Ulceration
No 142 (89.9) 31 (66.0) <0.001 70 (90.9) 15 (57.7) <0.001 72 (88.9) 16 (76.2) 0.134
Yes 16 (10.1) 16 (34.0) 7 (9.1) 11 (42.3) 9 (11.1) 5 (23.8)
Unknown 1 0 0 0 1 0
Clinical stage
1 121 (76.1) 20 (42.6) <0.001 60 (88.2) 13 (81.2) 0.459 61 (91.0) 7 (43.8) <0.001
2-4 14 (8.8) 12 (25.5) 8 (11.8) 3 (18.8) 6 (9.0) 9 (56.2)
Unknown 24 15 9 10 15 5
Vascular invasion
No 146 (91.8) 46 (97.9) 0.149 73 (94.8) 26 (100.0) 0.238 73 (89.0) 20 (95.2) 0.393
Yes 13 (8.2) 1 (2.1) 4 (5.2) 0 9 (11.0) 1 (4.8)
Unknown 0 0 0 0 0 0
Mitotic count
0/mm2 88 (55.3) 13 (27.7) 0.001 42 (54.5) 7 (26.9) 0.015 46 (56.1) 6 (28.6) 0.025
>= 1/mm2 71 (44.7) 34 (72.3) 35 (45.5) 19 (73.1) 36 (43.9) 15 (71.4)
Unknown 0 0 0 0 0 0
Lymphocytic infiltrate
None-mild 42 (26.4) 14 (29.8) 0.667 20 (26.0) 08 (30.8) 0.636 22 (27.2) 6 (28.6) 0.898
Moderate-brisk 116 (73.0) 33 (70.2) 57 (74.0) 18 (69.2) 59 (72.8) 15 (71.4)
Unknown 1 0 0 0 1 0
P-values refer to Mann Whitney U test for comparison of means and Chi square test for X × 2 tables. The categories marked as unknown were not included
in the analyses.
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the rate of increase of the incidence of melanoma is higher
in females than in males [25,26]. This might be explained
by the fact that intentional tanning, not least the use of
tanning beds, is more frequent in younger women [27-29].
Unfortunately, information on tanning habits is not avail-
able for participants in the MDCS.
The observation that Ki67 expression was a significant
predictor of an adverse clinical outcome in men but not in
women, also when adjusted for other factors, is intriguing.
Notably, gender had no modifying effect on the prognostic
value of mitotic index, another tumour characteristic
reflecting tumour proliferation, and Breslow thickness had
a similar impact on survival in both sexes. A prognostic
role for Ki67 expression is supported by several studies
[30-33], and, moreover, the rate of proliferation has been
demonstrated to decrease when melanoma cells enter the
dermis, corresponding to the transition from in situ to in-
vasive radial growth, and to increase again with the onset
of the vertical growth phase [33]. Information on growth
phase was not available for the patients in our study, and
Ki67 expression was assessed according to the estimated
proportion of all melanoma cells, without further fine-
tuning according to lesional compartment, since this
would have required analysis of full-face sections. Sex-
related differences have been demonstrated in the time
course and pattern of melanoma metastasis [14], and our
findings also indicate a potential influence of sex hor-
mones on the balance between invasion and proliferation
in the earlier phases of melanoma progression. Notably,
there was no significant difference between sexes in the
distribution or associations of mitotic index, tumour
thickness and Ki67 expression, that might explain the dif-
ferential prognostic impact of the latter in women and
men. There were however sex-related differences in the
associations of Ki67 expression with ulceration and Clark
level, both being strongly associated with Ki67 expression
in women but not in men. Moreover, in men, but not in
women, ulceration was an independent prognostic factor
for both DFS and OS. Of note, ulcerated melanoma has
been proposed to constitute a biologically distinct subtype
of melanoma [34], and, hence, our findings are of potential
interest, as they suggest that the clinical course of this
phenotype might be influenced by endocrine factors.
Use of the TMA technique for biomarker studies in
melanoma has several limitations, not least related to
technical difficulties to obtain qualitative tissue cores
from small lesions, thereby creating a selection bias to-
wards larger tumours available for analysis. The majority
of melanomas in our study were however thinner than
1 mm, also in the TMA cohort, and Ki67 remained an
independent predictor of an impaired DFS and OS in
men even after adjustment for tumour thickness, thus
supporting its prognostic value also in thinner melanomas.Another potential limitation to the TMA technique is that
heterogenously expressed markers might not be reliably
determined. The only investigative biomarker in this study,
Ki67, has been demonstrated to show variable expression in
melanoma, depending on the growth phase [33]. We did
however check for staining heterogeneity of Ki67 expres-
sion by comparing full-face sections and TMA cores from a
subset of the tumours and found no obvious difference.
Another limitation to our study is that the compara-
tively low number of recurrences did not allow for a
meaningful analysis of sex-related differences in the pre-
dilection of local, regional or distant recurrence. How-
ever, while the recurrence rate did not differ significantly
between the sexes, the finding of a significantly prolonged
survival in women compared to men after the first recur-
rence is consistent with previous studies [14].
Some of the findings in this study should be interpreted
with caution, since they represent results from post hoc
subgroup analyses of small numbers of patients. There-
fore, these data need to be validated in larger patient
cohorts. It should also be pointed out that since mean
age at diagnosis was 65 years for women, interpretations
relying on sex as evidence for influence of sex hormones
must be made with caution until further knowledge has
been gained. To this end, future studies are warranted to
explore the effects of e.g. hormone replacement therapy
on clinicopathological factors, molecular correlates and
survival from melanoma.
Conclusions
The prognostic value of tumour location, ulceration and
Ki67 expression in melanoma seems to differ according
to gender. These findings need to be validated in future
studies, as they might help improve prognostication of
patients with primary melanoma. Moreover, our data fur-
ther support the value of sex-stratified analyses in bio-
marker studies.
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